Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
138 hedge funds and large institutions have $313M invested in Keryx Biopharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 47 reducing their positions, and 34 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 47
10% less funds holding
Funds holding: 153 → 138 (-15)
34% less call options, than puts
Call options by funds: $3.99M | Put options by funds: $6M
41% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 34
66% less capital invested
Capital invested by funds: $915M → $313M (-$603M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$33.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.4M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$10.9M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$6.89M |
| 5 |
Goldman Sachs
New York
|
+$6.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$19.3M |
| 2 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$18.7M |
| 3 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$16M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$10.1M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.24M |
KERX Hedge Fund Activity: Q3 2015 in Review
138 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q3 2015, worth a combined $313M — down 66% from $915M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of KERX and 20 opened new positions — a net loss of 14 holders — while 47 trimmed existing stakes and 47 added.
The largest buyer was Abrams Capital Management, opening a new position worth an estimated $33.5M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $19.3M sold.
- 138 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q3 2015, down from 153 in Q2 2015.
- Funds reported $313M of Keryx Biopharmaceuticals Inc stock for Q3 2015, down 66% quarter-over-quarter.
- 20 funds opened new Keryx Biopharmaceuticals Inc positions in Q3 2015 and 34 closed out, a net change of -14 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q3 2015 was Abrams Capital Management, an estimated $33.5M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q3 2015 was Eagle Asset Management, an estimated $19.3M sold.
Based on aggregated 13F filings for Q3 2015.